Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Cellegy completes enrollment in phase III HIV prevention study of Savvy

Nov. 2, 2005

Phase II study discontinued for vicriviroc in treatment-naive HIV patients

Nov. 2, 2005

TNX-355 reported effective in reducing viral load of HIV-infected patients

Oct. 28, 2005

Aptivus for HIV receives European approval

Oct. 28, 2005

Indevus begins phase III of PRO-2000 to prevent STDs

Oct. 28, 2005

IDO - a target for anti-HIV therapy

Oct. 28, 2005

Enrollment stopped in phase III studies of ONO-4128

Oct. 27, 2005

Novel agents for HIV infection imparted in recent patent literature

Oct. 25, 2005

Maxygen supported in preventative HIV vaccine efforts

Oct. 25, 2005

Positive preclinical results for HIV protease inhibitor PPL-100

Oct. 21, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...